BioCryst PharmaceuticalsBCRX
BCRX
About: BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Employees: 580
0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
42% more call options, than puts
Call options by funds: $12.1M | Put options by funds: $8.5M
25% more funds holding in top 10
Funds holding in top 10: 4 [Q3] → 5 (+1) [Q4]
6% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 32
0% less funds holding
Funds holding: 255 [Q3] → 254 (-1) [Q4]
4% less capital invested
Capital invested by funds: $1.32B [Q3] → $1.26B (-$55.3M) [Q4]
2.77% less ownership
Funds ownership: 83.73% [Q3] → 80.96% (-2.77%) [Q4]
12% less repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 90
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$11
51%
upside
Avg. target
$17.33
137%
upside
High target
$30
311%
upside
6 analyst ratings
6 positive
100%
0 neutral
0%
0 negative
0%
Citizens Capital Markets Jonathan Wolleben 0 / 0 met price target | 147%upside $18 | Market Outperform Reiterated | 3 Mar 2025 |
RBC Capital Brian Abrahams 20% 1-year accuracy 14 / 70 met price target | 51%upside $11 | Outperform Reiterated | 25 Feb 2025 |
HC Wainwright & Co. Andrew Fein 32% 1-year accuracy 113 / 358 met price target | 311%upside $30 | Buy Reiterated | 25 Feb 2025 |
JMP Securities Jonathan Wolleben 0 / 0 met price target | 147%upside $18 | Market Outperform Reiterated | 31 Jan 2025 |
Evercore ISI Group Liisa Bayko 45% 1-year accuracy 5 / 11 met price target | 64%upside $12 | Outperform Maintained | 13 Jan 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
3 weeks ago
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., March 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted seven newly-hired employees restricted stock units (RSUs) covering an aggregate of 65,900 shares of BioCryst common stock. The RSUs were granted as of March 3, 2025, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Positive
Zacks Investment Research
1 month ago
BioCryst (BCRX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for BioCryst (BCRX) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Neutral
Zacks Investment Research
1 month ago
Here's Why BioCryst (BCRX) Could be Great Choice for a Bottom Fisher
After losing some value lately, a hammer chart pattern has been formed for BioCryst (BCRX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts Predict an 84.18% Upside in BioCryst (BCRX): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 84.2% in BioCryst (BCRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Positive
Seeking Alpha
1 month ago
BioCryst: Orladeyo's Expansion Is Just Getting Started
BioCryst Pharmaceuticals, a rare disease biotech, shows strong revenue growth from ORLADEYO, a healthy cash position, and a promising pipeline, making it an attractive investment. Despite a net loss, BioCryst's improved operating metrics and strategic focus on key assets like BCX17725 and avoralstat signal disciplined resource allocation and long-term growth. ORLADEYO's potential pediatric expansion could significantly boost market penetration and revenue, positioning BioCryst as a leader in hereditary angioedema treatment.
Positive
Seeking Alpha
1 month ago
BioCryst: Hold Steady As Orladeyo Builds, But Competition Heats Up
BioCryst Pharmaceuticals stock rose 9% since September, driven by strong Orladeyo sales and raised revenue guidance for 2025 to $535-$550 million. Orladeyo's convenience over injectable therapies is solidifying its market presence, with pediatric expansion and exclusivity until 2035 boosting growth prospects. Potential competition from Pharvaris' deucrictibant, but Orladeyo's market entrenchment and differentiation mitigate immediate threats.
Positive
Seeking Alpha
1 month ago
BioCryst: Upgrading On Strong 2024 Orladeyo Sales, But I Remain Skeptical
I initially rated BioCryst a "Sell" in November 2023, but am now upgrading to "Hold" as the company has outperformed my expectations, despite competitive pressures. Orladeyo, BioCryst's main revenue source, saw impressive growth in 2024, but faces significant competition and may not reach management's $1bn annual revenue target in my view. Q4 2024 earnings showed a notable improvement with a reduced GAAP operating loss and a positive non-GAAP operating profit, but guidance for ~22% growth led to a sell-off.
Negative
The Motley Fool
1 month ago
Why BioCryst Pharmaceuticals Stock Tumbled by 10% Today
Investors clearly weren't in a forgiving mood on Monday when it came to BioCryst Pharmaceuticals (BCRX -9.99%) stock. After the commercial-stage biotech published its fourth-quarter and full-year 2024 results, they traded its shares down by an even 10% on the day.
Neutral
Seeking Alpha
1 month ago
BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2024 Earnings Call Transcript
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ) Q4 2024 Earnings Conference Call February 24, 2025 8:30 AM ET Company Participants John Bluth - Chief Communications Officer Jon Stonehouse - CEO Charlie Gayer - Chief Commercial Officer Helen Thackray - Chief R&D Officer Anthony Doyle - CFO Conference Call Participants Tazeen Ahmad - Bank of America Jessica Fye - JP Morgan Stacy Ku - TD Cowen Brian Abrahams - RBC Capital Markets Gena Wang - Barclays Jonathan Wolleben - Citizens JMP Seema Sheoran - Evercore ISI Serge Belanger - Needham & Company Maury Raycroft - Jefferies Operator Good morning, and welcome to the BioCryst Fourth Quarter 2024 Earnings Call. All participants will be in listen-only mode.
Neutral
Benzinga
1 month ago
BioCryst Pharmaceuticals Unveils Latest Trial Data, Reports Mixed Q4 Earnings
On Monday, BioCryst Pharmaceuticals, Inc. BCRX released results from an interim analysis of the ongoing APeX-P trial.
Charts implemented using Lightweight Charts™